Pictet Asset Management Holding SA Acquires 20,777 Shares of BioNTech SE Sponsored ADR $BNTX

Pictet Asset Management Holding SA increased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 11.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 206,580 shares of the company’s stock after buying an additional 20,777 shares during the quarter. Pictet Asset Management Holding SA’s holdings in BioNTech were worth $20,363,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC grew its holdings in BioNTech by 4.5% in the 3rd quarter. AlphaCentric Advisors LLC now owns 6,547 shares of the company’s stock valued at $644,000 after buying an additional 281 shares during the period. Parallel Advisors LLC lifted its holdings in shares of BioNTech by 50.3% during the 3rd quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock worth $83,000 after acquiring an additional 282 shares during the period. Privium Fund Management B.V. lifted its holdings in shares of BioNTech by 6.6% during the 3rd quarter. Privium Fund Management B.V. now owns 32,100 shares of the company’s stock worth $3,155,000 after acquiring an additional 2,000 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of BioNTech in the third quarter worth approximately $614,000. Finally, Profund Advisors LLC boosted its position in shares of BioNTech by 12.1% in the third quarter. Profund Advisors LLC now owns 5,159 shares of the company’s stock worth $507,000 after acquiring an additional 555 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BNTX. Wells Fargo & Company lowered their target price on shares of BioNTech from $140.00 to $125.00 and set an “overweight” rating for the company in a report on Wednesday, November 4th. BMO Capital Markets lowered BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. HC Wainwright reduced their target price on BioNTech from $130.00 to $110.00 and set a “buy” rating on the stock in a report on Monday. UBS Group lowered their price target on BioNTech from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Finally, Bank of America restated a “buy” rating on shares of BioNTech in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.27.

Insider Activity

In other news, CEO Ugur Sahin sold 36,209 shares of the business’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 807,209 shares of company stock worth $79,246,837 in the last 90 days. Company insiders own 19.20% of the company’s stock.

BioNTech Price Performance

BNTX opened at $87.65 on Thursday. The company has a quick ratio of 8.52, a current ratio of 8.55 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a 50 day moving average of $93.80 and a two-hundred day moving average of $96.25. The company has a market cap of $22.17 billion, a P/E ratio of -12.80 and a beta of 1.28.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.